Ribavirin and interferon therapy in patients infected with the Middle East respiratory syndrome coronavirus: an observational study.
Ribavirin and interferon therapy in patients infected with the Middle East respiratory syndrome coronavirus: an observational study.
复制标题
DOI：
10.1016/j.ijid.2013.12.003
复制
发表时间：
2014-03
期刊：
影响因子：
--
通讯作者：
Memish ZA
中科院分区：
文献类型：
--
作者：
Al-Tawfiq JA;Momattin H;Dib J;Memish ZA
据报道，中东呼吸综合征冠状病毒（MERS-CoV）的病死率很高。目前，尚无已证实对中东呼吸综合征冠状病毒感染有效的特效疗法或疫苗。利巴韦林和干扰素联合疗法用于治疗五名中东呼吸综合征冠状病毒阳性患者。我们回顾了这些患者的治疗方案和结果。所有患者均患有急性呼吸窘迫综合征，病情危重，接受皮质类固醇辅助治疗，并在开始治疗时接受机械通气。从入院到利巴韦林和干扰素治疗的中位时间为 19 天（范围 10-22）。没有一名患者对支持性或治疗性干预措施有反应，并且全部死于疾病。虽然利巴韦林和干扰素可能对某些患者有效，但我们的实践经验表明，在病程晚期诊断出的患有多种合并症的危重患者可能无法像临床前数据所显示的那样从联合抗病毒治疗中受益。显然，迫切需要一种新型有效的抗病毒疗法来应对这一新出现的全球威胁。
The Middle East respiratory syndrome coronavirus (MERS-CoV) has been reported to have a high case-fatality rate. Currently, there is no specific therapy or vaccine with proven effectiveness for MERS-CoV infections. A combination of ribavirin and interferon therapy was used for the treatment of five MERS-CoV-positive patients. We reviewed the therapeutic schedule and the outcome of these patients. All patients were critically ill with acute respiratory distress syndrome treated with adjunctive corticosteroids and were on mechanical ventilation at the time of initiation of therapy. The median time from admission to therapy with ribavirin and interferon was 19 (range 10–22) days. None of the patients responded to the supportive or therapeutic interventions and all died of their illness. While ribavirin and interferon may be effective in some patients, our practical experience suggests that critically ill patients with multiple comorbidities who are diagnosed late in the course of their illness may not benefit from combination antiviral therapy as preclinical data suggest. There is clearly an urgent need for a novel effective antiviral therapy for this emerging global threat.
登录
查看更多内容
影响因子：
3.3
作者：
Leong, HN;Ang, B;Leo, YS
通讯作者：
Leo, YS
DOI：
10.1016/j.ijid.2013.07.002
发表时间：
2013-10
期刊：
International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases
影响因子：
--
作者：
Momattin H;Mohammed K;Zumla A;Memish ZA;Al-Tawfiq JA
通讯作者：
Al-Tawfiq JA
DOI：
10.1056/nejmoa1306742
发表时间：
2013-08-01
期刊：
The New England journal of medicine
影响因子：
--
作者：
Assiri A;McGeer A;Perl TM;Price CS;Al Rabeeah AA;Cummings DA;Alabdullatif ZN;Assad M;Almulhim A;Makhdoom H;Madani H;Alhakeem R;Al-Tawfiq JA;Cotten M;Watson SJ;Kellam P;Zumla AI;Memish ZA;KSA MERS-CoV Investigation Team
通讯作者：
KSA MERS-CoV Investigation Team
影响因子：
82.9
作者：
通讯作者：
--
影响因子：
19
作者：
Penttinen, P. M.;Kaasik-Aaslav, K.;Coulombier, D.
通讯作者：
Coulombier, D.